News | October 18, 2011

Wall Street Journal Award Recognizes Abbott’s Absorb Stent

October 18, 2011 — Abbott announced the investigational Absorb bioresorbable vascular scaffold (BVS) has been recognized as the winner of the Medical Devices category in the 2011 Wall Street Journal Technology Innovation Awards. Absorb is an implantable device that restores blood flow by opening a blocked artery and providing support to the vessel until the device dissolves. Once in place, the device dissolves in approximately two years, leaving patients with a treated vessel free of a permanent metallic implant.

The first drug eluting device of its kind for coronary artery disease (CAD), Absorb is made of polylactide, a proven biocompatible material commonly used in medical implants. Because a permanent metallic implant is not left behind, naturally occurring vessel functions may be restored

"Absorb represents the best in scientific innovation, as it has the potential to change the way physicians practice medicine and improve outcomes for their patients," said Robert B. Hance, senior vice president, vascular, Abbott. "We are pleased that this innovation, which has been developed in the U.S. over nearly a decade, has the prospect of advancing patient care around the globe. Abbott is honored to receive this prestigious award."

In January 2011, Abbott announced that the device received CE mark in Europe for the treatment of CAD. In the United States, it currently is under development and is not available for sale. The device is being evaluated in more than 40 clinical centers in 20 countries around the world.

In 2010, Abbott was a runner-up in the Medical Devices category of Technology Innovation Awards for its investigational MitraClip system. In 2009, the company’s Ibis T5000 Biosensor system was honored as the category winner in Medicine-Biotech and received the overall Gold Award across all the categories. In 2007, the Humira self-injectable treatment for Crohn's disease was a runner-up in the Medical-Biotech category.

In its 11th year, The Wall Street Journal Technology Innovation Awards assessed applications on three criteria: whether the innovation breaks with conventional ideas or processes in its field; whether it goes beyond marginal improvements of an existing technology; and whether it will have a wide impact in its field or on future technology.

This year, the newspaper received 605 entries from companies, organizations and individuals in 31 countries. The judges chose 35 winners and runners up in 16 categories. The independent panel of judges included individuals from venture-capital firms, universities and other organizations and companies.

For more information: www.abbott.com

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Overlay Init